RINGSIDE
06 Dec 2021
RINGSIDE
NCT04871282
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
Ayala Pharmaceuticals, Inc
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase II, Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | All stages |
Anticipated Start Date | 2021-03-30 |
Anticipated End Date | 2025-01-12 |
Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
---|---|
Clinical Trial Coordinator | Sue Yeend |
Sue.Yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Nimit Singhal |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs